DK1140139T3 - Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier - Google Patents

Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier

Info

Publication number: DK1140139T3
Authority: DK; Denmark
Prior art keywords: erythropoietin; cerebral; treatment; ischaemia; derivatives
Prior art date: 1998-12-14

Application number

DK99966958T

Other languages

English (en)

Other versions

DK1140139T4 (da

Inventor

Hannelore Ehrenreich

Christophe Gleiter

Original Assignee

Hannelore Ehrenreich

Christophe Gleiter

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-14

Filing date

1999-12-13

Publication date

2004-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1140139(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-13 Application filed by Hannelore Ehrenreich, Christophe Gleiter filed Critical Hannelore Ehrenreich

2004-03-15 Application granted granted Critical

2004-03-15 Publication of DK1140139T3 publication Critical patent/DK1140139T3/da

2009-06-08 Publication of DK1140139T4 publication Critical patent/DK1140139T4/da

Links

OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 5
102000003951 Erythropoietin Human genes 0.000 title abstract 4
108090000394 Erythropoietin Proteins 0.000 title abstract 4
229940105423 erythropoietin Drugs 0.000 title abstract 4
230000002490 cerebral effect Effects 0.000 title abstract 3
235000015243 ice cream Nutrition 0.000 title 1
206010008120 Cerebral ischaemia Diseases 0.000 abstract 3
208000006011 Stroke Diseases 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)

DK99966958T 1998-12-14 1999-12-13 Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier DK1140139T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19857609A DE19857609A1 (de)	1998-12-14	1998-12-14	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PCT/EP1999/009864 WO2000035475A2 (de)	1998-12-14	1999-12-13	Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien

Publications (2)

Publication Number	Publication Date
DK1140139T3 true DK1140139T3 (da)	2004-03-15
DK1140139T4 DK1140139T4 (da)	2009-06-08

Family

ID=7891015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99966958T DK1140139T4 (da)	1998-12-14	1999-12-13	Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier

Country Status (26)

Country	Link
US (1)	US7514072B1 (da)
EP (1)	EP1140139B2 (da)
JP (2)	JP4750947B2 (da)
KR (1)	KR100774827B1 (da)
CN (1)	CN1187085C (da)
AT (1)	ATE253932T1 (da)
AU (1)	AU766216C (da)
BG (1)	BG65417B1 (da)
BR (1)	BR9916197A (da)
CA (1)	CA2353553C (da)
DE (2)	DE19857609A1 (da)
DK (1)	DK1140139T4 (da)
ES (1)	ES2211218T5 (da)
HK (1)	HK1042655B (da)
HU (1)	HUP0104709A3 (da)
ID (1)	ID29107A (da)
IL (2)	IL143579A0 (da)
MX (1)	MXPA01005971A (da)
NO (1)	NO330079B1 (da)
NZ (1)	NZ541591A (da)
PL (1)	PL202483B1 (da)
PT (1)	PT1140139E (da)
RO (1)	RO121409B1 (da)
RU (1)	RU2242991C2 (da)
WO (1)	WO2000035475A2 (da)
ZA (1)	ZA200104626B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7309687B1 (en)	1999-04-13	2007-12-18	The Kenneth S. Warren Institute, Inc.	Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
KR101012932B1 (ko) *	1999-04-13	2011-02-08	더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드	말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US7345019B1 (en)	1999-04-13	2008-03-18	The Kenneth S. Warren Institute, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
US7078376B1 (en)	2000-08-11	2006-07-18	Baxter Healthcare S.A.	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) *	2000-09-04	2002-03-28	Hannelore Ehrenreich	Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) *	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en)	2000-12-29	2003-03-11	The Kenneth S. Warren Institute, Inc.	Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AR036400A1 (es)	2001-08-30	2004-09-08	Stem Cell Therapeutics Inc	Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de)	2001-09-14	2012-02-15	Stem Cell Therapeutics Inc	Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
DE10219545A1 (de) *	2002-04-26	2003-11-06	Lang Florian	Regulation der Apoptose
US7439063B2 (en) *	2002-06-11	2008-10-21	Burnham Institute For Medical Research	Neuroprotective synergy of erythropoietin and insulin-like growth factors
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
EP1633383A4 (en) *	2003-03-27	2008-05-21	Janssen Pharmaceutica Nv	USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US7718363B2 (en)	2003-04-25	2010-05-18	The Kenneth S. Warren Institute, Inc.	Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) *	2003-07-31	2007-05-17	Stem Cell Therapeutics Inc.	Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005032467A2 (en)	2003-09-29	2005-04-14	Warren Pharmaceuticals, Inc.	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
UA82561C2 (uk) *	2003-10-23	2008-04-25	Оцука Фармасьютикалз Ко., Лтд.	Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
CA2556266A1 (en)	2004-02-13	2005-08-25	Stem Cell Therapeutics Corp.	Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en)	2005-05-13	2018-06-05	Charite Universitaetsmedizen-Berlin	Erythropoietin variants
EP1736481A1 (en)	2005-05-13	2006-12-27	Charite Universitätsmedizin-Berlin	Erythropoietin variants
CA2622758A1 (en) *	2005-09-15	2007-03-29	Elan Pharma International, Limited	Nanoparticulate aripiprazole formulations
WO2007036033A1 (en) *	2005-09-27	2007-04-05	Stem Cell Therapeutics Corp.	Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2007106987A1 (en) *	2006-03-17	2007-09-27	Stem Cell Therapeutics Corp.	Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
BRPI0712063A2 (pt) *	2006-06-07	2011-12-20	Chugai Pharmaceutical Co Ltd	tratamento de doenças isquêmicas usando eritropoietina
SI2170279T1 (en) *	2007-07-31	2018-04-30	Otsuka Pharmaceutical Co., Ltd.	Methods for producing aripiprazole suspension and freeze-dried formulation
RU2446834C2 (ru) *	2010-06-15	2012-04-10	Елена Александровна Лебедева	Способ лечения пострадавших с сочетанной черепно-мозговой травмой
WO2012148200A2 (ko)	2011-04-26	2012-11-01	아주대학교 산학협력단	허혈성 혈관 질환 치료시술 보조용 조성물
RU2495688C1 (ru) *	2012-03-28	2013-10-20	Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии"	Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en)	2013-03-15	2017-04-04	Pacesetter, Inc.	Erythropoeitin production by electrical stimulation
KR20190052855A (ko)	2017-11-09	2019-05-17	대한제당 주식회사	페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ210501A (en)	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) *	1986-11-21	1991-05-07	Amgen, Inc.	Method for treating iron overload using EPO
FR2646438B1 (fr)	1989-03-20	2007-11-02	Pasteur Institut	Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0945515A3 (en)	1989-11-06	2002-08-21	Cell Genesys, Inc.	Production of proteins using homologous recombination
ES2151463T5 (es)	1989-12-22	2012-10-29	Merck Serono Sa	Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US5750376A (en)	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
PT101031B (pt)	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
JP3537151B2 (ja)	1991-12-26	2004-06-14	中外製薬株式会社	脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) *	1992-03-19	1996-10-27	Учебно-научный центр Медицинского центра при Правительстве РФ	Способ профилактики церебро-васкулярных заболеваний
US5614184A (en)	1992-07-28	1997-03-25	New England Deaconess Hospital	Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en)	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
BR9406490A (pt)	1993-04-29	1996-03-05	Abbott Lab	Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo
CN1057534C (zh)	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
SE520730C2 (sv)	1995-01-20	2003-08-19	Eskil Elmer	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en)	1995-10-20	2000-09-19	St. Elizabeth's Medical Center Of Boston, Inc.	Method for treating ischemic tissue
US6165783A (en)	1997-10-24	2000-12-26	Neuro Spheres Holdings Ltd.	Erythropoietin-mediated neurogenesis
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko)	1999-04-13	2011-02-08	더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드	말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

1998
- 1998-12-14 DE DE19857609A patent/DE19857609A1/de not_active Ceased
1999
- 1999-12-13 PL PL349335A patent/PL202483B1/pl not_active IP Right Cessation
- 1999-12-13 CA CA2353553A patent/CA2353553C/en not_active Expired - Fee Related
- 1999-12-13 HU HU0104709A patent/HUP0104709A3/hu unknown
- 1999-12-13 HK HK02104485.2A patent/HK1042655B/zh not_active IP Right Cessation
- 1999-12-13 BR BR9916197-4A patent/BR9916197A/pt not_active Application Discontinuation
- 1999-12-13 US US09/868,089 patent/US7514072B1/en not_active Expired - Fee Related
- 1999-12-13 KR KR1020017007421A patent/KR100774827B1/ko not_active Expired - Fee Related
- 1999-12-13 RU RU2001116077/14A patent/RU2242991C2/ru not_active IP Right Cessation
- 1999-12-13 DE DE59907752T patent/DE59907752D1/de not_active Expired - Lifetime
- 1999-12-13 AU AU22831/00A patent/AU766216C/en not_active Ceased
- 1999-12-13 WO PCT/EP1999/009864 patent/WO2000035475A2/de not_active Ceased
- 1999-12-13 PT PT99966958T patent/PT1140139E/pt unknown
- 1999-12-13 JP JP2000587794A patent/JP4750947B2/ja not_active Expired - Fee Related
- 1999-12-13 EP EP99966958A patent/EP1140139B2/de not_active Expired - Lifetime
- 1999-12-13 MX MXPA01005971A patent/MXPA01005971A/es active IP Right Grant
- 1999-12-13 DK DK99966958T patent/DK1140139T4/da active
- 1999-12-13 AT AT99966958T patent/ATE253932T1/de active
- 1999-12-13 CN CNB998160474A patent/CN1187085C/zh not_active Expired - Fee Related
- 1999-12-13 IL IL14357999A patent/IL143579A0/xx active IP Right Grant
- 1999-12-13 ES ES99966958T patent/ES2211218T5/es not_active Expired - Lifetime
- 1999-12-13 RO ROA200100684A patent/RO121409B1/ro unknown
- 1999-12-13 ID IDW00200101535A patent/ID29107A/id unknown
- 1999-12-13 NZ NZ541591A patent/NZ541591A/en not_active IP Right Cessation
2001
- 2001-06-05 IL IL143579A patent/IL143579A/en not_active IP Right Cessation
- 2001-06-06 ZA ZA200104626A patent/ZA200104626B/en unknown
- 2001-06-07 BG BG105575A patent/BG65417B1/bg unknown
- 2001-06-12 NO NO20012896A patent/NO330079B1/no not_active IP Right Cessation
2010
- 2010-12-20 JP JP2010283105A patent/JP2011079860A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
BG105575A (en)	2002-01-31
AU2283100A (en)	2000-07-03
HK1042655A1 (en)	2002-08-23
DK1140139T4 (da)	2009-06-08
WO2000035475A2 (de)	2000-06-22
KR20010082346A (ko)	2001-08-29
ES2211218T3 (es)	2004-07-01
NO20012896D0 (no)	2001-06-12
DE59907752D1 (de)	2003-12-18
PL349335A1 (en)	2002-07-15
PL202483B1 (pl)	2009-06-30
ES2211218T5 (es)	2009-06-03
WO2000035475A3 (de)	2000-10-19
JP4750947B2 (ja)	2011-08-17
EP1140139A2 (de)	2001-10-10
IL143579A0 (en)	2002-04-21
AU766216C (en)	2004-11-11
BR9916197A (pt)	2001-09-04
HUP0104709A2 (hu)	2002-04-29
NO330079B1 (no)	2011-02-14
HUP0104709A3 (en)	2002-05-28
KR100774827B1 (ko)	2007-11-07
CA2353553C (en)	2011-05-17
NZ541591A (en)	2007-08-31
EP1140139B1 (de)	2003-11-12
CN1187085C (zh)	2005-02-02
NO20012896L (no)	2001-08-14
HK1042655B (zh)	2005-09-23
JP2011079860A (ja)	2011-04-21
DE19857609A1 (de)	2000-06-15
MXPA01005971A (es)	2002-03-27
PT1140139E (pt)	2004-04-30
RU2242991C2 (ru)	2004-12-27
ZA200104626B (en)	2002-09-06
CN1335776A (zh)	2002-02-13
ATE253932T1 (de)	2003-11-15
US7514072B1 (en)	2009-04-07
RO121409B1 (ro)	2007-05-30
CA2353553A1 (en)	2000-06-22
AU766216B2 (en)	2003-10-09
JP2002532432A (ja)	2002-10-02
EP1140139B9 (de)	2004-03-31
BG65417B1 (bg)	2008-07-31
EP1140139B2 (de)	2009-03-18
IL143579A (en)	2007-10-31
ID29107A (id)	2001-07-26

Publication	Publication Date	Title
DK1140139T4 (da)	2009-06-08	Anvendelse af erythropoietin eller erythropoietinderivater til behandling af cerebrale iskræmier
EP4442241A3 (en)	2024-12-25	Retinol replacement in skin treatment
EA200800056A1 (ru)	2008-06-30	Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
DK1289517T3 (da)	2006-04-03	Farmaceutiske sammensætninger indeholdende cannabidiolderivater
WO2004096216A3 (en)	2005-04-14	Use of a topical medicament comprising riluzole
ATE200422T1 (de)	2001-04-15	Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
NO975192D0 (no)	1997-11-12	Bicykliske aromatiske forbindelser
WO2004100893A3 (en)	2005-07-28	Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2007046097A3 (en)	2009-04-09	Topical compositions for the treatment of depilation-induced skin irritation or prevention thereof
ATE141045T1 (de)	1996-08-15	Schlankmachende zusammensetzung
NZ328874A (en)	1999-06-29	Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
TW200510352A (en)	2005-03-16	Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
FR2746098B1 (fr)	1998-04-30	Composes propynyl biaromatiques
BR0310061A (pt)	2005-03-01	Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
KR102163775B9 (ko)	2022-07-18	7-벤질-4-7H-피롤로[2,3-d]피리미딘 유도체 및 이를 유효성분으로 함유하는 피부 미백용 조성물 및 멜라닌 색소 과다 침착 질환의 예방 또는 치료용 약학적 조성물
ATE241640T1 (de)	2003-06-15	Fusidinsäure-derivate
NO20021241L (no)	2002-03-13	Farmasöytiske og/eller kosmetiske blandinger
IS2392B (is)	2008-08-15	Sítalópram til að meðhöndla hækkaðan blóðþrýsting
DE60228687D1 (de)	2008-10-16	Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
TW200508229A (en)	2005-03-01	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
BR0312283A (pt)	2005-04-12	Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
IT1310326B1 (it)	2002-02-13	Pomata per la cura delle lesioni cutanee particolarmente delle ustioni
BR0214644A (pt)	2004-11-03	Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação
BR9909530A (pt)	2000-12-26	Tratamento de doenças parasitárias pela inibição das proteases de cisteìna da superfamìlia da papaìna